Edifier MR4 Powered Studio Monitor 2.0 Speakers 42 Watts (Black)

Product Information

Hughes T, Deininger M, Hochhaus A. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108(1):28-37. https://doi.org/10.1182/blood-2006-01-0092 PubMed PubMed Central Google Scholar Mobius S, Schenk T, Himsel D. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). J Cancer Res Clin Oncol. 2019; 145(6):1645-1650. https://doi.org/10.1007/s00432-019-02910-6 PubMed Google Scholar

Clark RE, Polydoros F, Apperley JF. Deescalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019; 6(7):e375-e383. https://doi.org/10.1016/S2352-3026(19)30094-8 Google ScholarTreatment free remission (TFR) in chronic myeloid leukaemia (CML), is when you stop tyrosine kinase inhibitor (TKI) treatment after a time of remission. Boulton, Marc and Mike Sweeney. "News release: Nimrod MRA4 Releases Sting Ray for First Time." BAE Systems, 30 July 2007. Retrieved: 20 October 2010. Note that you can get part of the way there by using the rear HF control and boosting a few dB (per listening tests and measurements). Once there, you do have good sound without having to deploy EQ. Etienne G, Dulucq S, Nicolini F-E. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014; 99(3):458-464. https://doi.org/10.3324/haematol.2013.095158 PubMed PubMed Central Google Scholar Nimrod MRA4 First Flight". Defence Procurement Agency. 20 September 2005. Archived from the original on 12 October 2005.

Optimal response associated with best long-term outcome —> achieving MMR (<0.1%) predicts a CML-specific life expectancy the same as that of the general population Ripley, Time. "RAF 'super-base' plan leaves future of Kinloss in doubt". scotsman.com, 6 September 2004. As the Edifier MR4 studio monitors are fully analog, the feature set is pretty light compared to many other computer monitors. However, they do come with one interesting feature and that’s its dual sound effect modes. There’s a monitor and a music mode on hand, and you switch between the two by pressing the power dial. The LED that indicates that the speakers are on switches between red for monitor and green for music mode. Like the EQ dials, the effect is pretty subtle, but the music mode does seem to boost the mid-highs a little to give the audio a little more presence while the monitor mode gives a more neutral frequency response. Branford S, Seymour JF, Grigg A. BCRABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007; 13(23):7080-7085. https://doi.org/10.1158/1078-0432.CCR-07-0844 PubMed Google Scholar I expected the Music mode to have much more exaggerated lows and highs but instead, it seems to have a more even on-axis response. Getting to the same place with the HF control requires boosting it to the 2 dB marker.British P-8 Poseidon aircraft are armed with American weapons, which makes sense given the relatively small fleet the UK will be operating.

There are differences of opinion between experts regarding the early molecular response milestone values. Table 1 compares these values between the recent updated ELN recommendations 19 and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines. 20 The NCCN guidelines have less stringent BCR-ABL1 cut-off values at 6 months (≤10%) and 12 months (≤1%) for TKI-sensitive disease (no change of therapy required). The ELN cut-off values for an optimal response are ≤1% at 6 months and ≤0.1% at 12 months (no change of therapy required). Furthermore, the ELN now considers a BCR-ABL1 value of ≤0.01% at any time as the optimal response for patients aiming for TFR. The ELN has a buffer response criterion of ‘warning’ between each milestone BCR-ABL1 cut-off value. A recommendation in cases of ‘warning’ is additional molecular monitoring if the kinetics of response is not clear. The trend of BCR-ABL1 decline over time can aid clinical decisions. 54 , 55 The NCCN also suggests assessing the trend of decline for patients with BCR-ABL1 only slightly >10% at 3 months before making drastic decisions regarding the treatment strategy. The definition of TKI-resistant disease after 12 months of TKI therapy is less stringent in the NCCN guidelines than in the ELN recommendations: BCR-ABL1 cut-off >10% for the NCCN and >1% for the ELN (ELN ‘Failure’ category). TFR is not suitable for everyone. There are strict criteria that you need to meet before you might be suitable for TRF. Kantarjian HM, Shah NP, Cortes JE. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2- year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119(5):1123-1129. https://doi.org/10.1182/blood-2011-08-376087 PubMed PubMed Central Google ScholarLate ‘off-target’ effects on CVS, heart, lungs, liver, pancreas, immune defense, glucose and secondary malignancies